文献速递急性肾损伤水电解质与酸碱

弥漫大B细胞淋巴瘤CAR-T治疗后急性肾损伤与电解质异常

Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma.
PubMed 文献 · Am J Kidney Dis · 2020-01-20

该病例系列回顾了78例接受CAR-T(阿基仑赛或替沙仑赛)治疗的弥漫大B细胞淋巴瘤成人患者,细胞因子释放综合征发生率为85%。急性肾损伤发生率为19%,其中8例肾灌注不足、6例急性肾小管坏死、1例尿路梗阻;低磷血症、低钾血症和低钠血症分别占75%、56%和51%。

要点

  • CAR-T治疗后急性肾损伤和电解质异常常见,多发生于细胞因子释放综合征背景下。
  • 急性肾损伤原因以肾灌注不足和急性肾小管坏死为主,后者住院时间更长、60天死亡率更高。
  • 低磷血症、低钾血症和低钠血症发生率分别为75%、56%和51%。

核心结论

  • 在接受CAR-T治疗的弥漫大B细胞淋巴瘤患者中,急性肾损伤和电解质异常常见,且多与细胞因子释放综合征相关。

研究设计与样本

  • 急性肾损伤采用KDIGO标准定义,通过电子健康记录评估CAR-T输注后30天内的原因、临床过程和结局。

主要发现

  • 细胞因子释放综合征发生于85%的患者,其中62%接受了托珠单抗治疗。
  • 急性肾损伤发生于15例(19%):8例肾灌注不足,6例急性肾小管坏死,1例疾病进展相关尿路梗阻。
  • 急性肾小管坏死和梗阻患者住院时间最长、60天死亡率最高。
  • 电解质异常常见:低磷血症75%、低钾血症56%、低钠血症51%。

临床怎么用

  • CAR-T治疗后应监测肾功能和电解质,尤其发生细胞因子释放综合征时。
  • 对出现急性肾损伤者需鉴别肾灌注不足、急性肾小管坏死和尿路梗阻等原因。

局限性

  • 样本量小。
  • 急性肾损伤判定基于回顾性病历审查。
  • 缺乏活检数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Cytokine release syndrome is a well-known complication of chimeric antigen receptor T-cell (CAR-T) therapy and can lead to multiorgan dysfunction. However, the nephrotoxicity of CAR-T therapy is unknown. We aimed to characterize the occurrence, cause, and outcomes of acute kidney injury (AKI), along with the occurrence of electrolyte abnormalities, among adults with diffuse large B-cell lymphoma receiving CAR-T therapy. STUDY DESIGN: Case series. SETTING & PARTICIPANTS: We reviewed the course of 78 adults receiving CAR-T therapy with axicabtagene ciloleucel or tisagenlecleucel at 2 major cancer centers between October 2017 and February 2019. Baseline demographics, comorbid conditions, medications, and laboratory values were obtained from electronic health records. AKI was defined using KDIGO (Kidney Disease: Improving Global Outcomes) criteria. The cause, clinical course, and outcome of AKI events and electrolyte abnormalities in the first 30 days after CAR-T infusion were characterized using data contained in electronic health records. RESULTS: Among 78 patients receiving CAR-T therapy, cytokine release syndrome occurred in 85%, of whom 62% were treated with tocilizumab. AKI occurred in 15 patients (19%): 8 had decreased kidney perfusion, 6 developed acute tubular necrosis, and 1 patient had urinary obstruction related to disease progression. Those with acute tubular necrosis and obstruction had the longest lengths of stay and highest 60-day mortality. Electrolyte abnormalities were common; hypophosphatemia, hypokalemia, and hyponatremia occurred in 75%, 56%, and 51% of patients, respectively. LIMITATIONS: Small sample size; AKI adjudicated by retrospective chart review; lack of biopsy data. CONCLUSIONS: In this case series of patients with diffuse large B-cell lymphoma receiving CAR-T therapy, AKI and electrolyte abnormalities occurred commonly in the context of cytokine release syndrome.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Gupta S, Seethapathy H, Strohbehn IA, et al. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. Am J Kidney Dis. 2020. PMID: 31973908. doi:10.1053/j.ajkd.2019.10.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。